<DOC>
	<DOCNO>NCT00919711</DOCNO>
	<brief_summary>A randomized , open label study assess safety effectiveness Denosumab , administer every 6 month Actonel 速 ( Risedronate ) , administer monthly post menopausal woman transition weekly daily Alendronate therapy .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Denosumab Actonel速 Post Menopausal Women Transitioned From Alendronate Therapy</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Ambulatory , post menopausal woman age 55 year old screening . Have receive first prescription daily weekly alendronate therapy , treatment post menopausal osteoporosis least 1 month prior screen . Use raloxifene , calcitonin hormone replacement therapy ( HRT ) prior alendronate treatment allow . Prior and/or current use vitamin D calcium allow . Has stop oral alendronate therapy ( denoted nonpersistent ) screen visit , still take oral alendronate therapy take regular basis ( assessed completion compliance questionnaire screening ) . Provide sign informed consent studyspecific procedure conduct . Any prior current use medication prescribe osteoporosis treatment oral daily alendronate , calcium vitamin D. Prior use raloxifen , calcitonin HRT alendronate therapy start allow . Hypersensitivity Actonel速 ingredient Actonel速 tablet . Contraindicated poorly tolerant alendronate therapy . Active gastric duodenal ulcer . Known sensitivity mammalian cell derive product . Known intolerance calcium supplement . Malignancy within last 5 year ( except cervical basal cell carcinoma ) . Vitamin D deficiency ( serum 25OH vitamin D le 20ng/mL ( equivalent 49.9 nanomoles per Liter ) screening . Current hypo hypercalcemia base central laboratory reference range . Uncontrolled hyper hypothyroidism ( stable antithyroid therapy postablation allow , laboratory result screen show thyroid stimulate hormone ( TSH ) within normal range ) . Any metabolic bone disease , e.g. , osteomalacia osteogenesis imperfecta , Paget 's disease bone may interfere interpretation finding . Height , weight girth may preclude accurate dual xray absorptiometry ( DXA measurement ) . Fewer 2 lumbar vertebra ( L1L4 ) able evaluate DXA . Known test positive human immunodeficiency virus . Previous participation clinical trial denosumab within last 12 month ( regardless treatment ) . Any laboratory abnormality , physical psychiatric disorder ( include substance abuse last 12 month ) , opinion investigator , prevent subject give write informed consent complete study interfere interpretation study result . Currently enrol within 30 day end another investigational device drug trial ( ) .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Menopausal Osteoporosis</keyword>
</DOC>